Revenue Insights: United Therapeutics Corporation and Supernus Pharmaceuticals, Inc. Performance Compared

Biopharma Revenue Growth: United vs. Supernus

__timestampSupernus Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 20141220450001288519000
Thursday, January 1, 20151444270001465761000
Friday, January 1, 20162150030001598800000
Sunday, January 1, 20173022380001725300000
Monday, January 1, 20184088970001627800000
Tuesday, January 1, 20193927550001448800000
Wednesday, January 1, 20205203970001483300000
Friday, January 1, 20215797750001685500000
Saturday, January 1, 20226672380001936300000
Sunday, January 1, 20236075210002327500000
Loading chart...

In pursuit of knowledge

Revenue Growth: A Tale of Two Biopharmaceutical Giants

In the competitive landscape of biopharmaceuticals, United Therapeutics Corporation and Supernus Pharmaceuticals, Inc. have showcased remarkable revenue trajectories over the past decade. From 2014 to 2023, United Therapeutics consistently outperformed, with revenue peaking at approximately $2.3 billion in 2023, marking an impressive 80% increase from 2014. Meanwhile, Supernus Pharmaceuticals demonstrated a robust growth pattern, achieving a revenue increase of over 400% during the same period, reaching around $607 million in 2023.

A Decade of Transformation

United Therapeutics maintained a steady revenue stream, with a notable surge in 2023, reflecting strategic advancements and market expansion. Supernus Pharmaceuticals, though smaller in scale, exhibited a dynamic growth curve, particularly between 2016 and 2022, highlighting its aggressive market penetration and product innovation. This comparative analysis underscores the diverse strategies and market responses of these two industry leaders, offering valuable insights into their financial evolution.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025